AstraZeneca, Daiichi Sankyo sign $6B deal for antibody-drug conjugate
The companies will share development and commercialization of DS-1062 in solid tumors. They already have a similar deal in place, the $6.9 billion agreement signed last year for another ADC, the HER2-positive breast cancer drug Enhertu.